Jianjia Robots, a Chinese orthopedic surgical robot developer has secured RMB100 million an equivalence US$14.62 million in a series B funding round per the statement released.
Participating investors in the round include Beijing-based private equity firm Hillhouse Capital, Chinese pharma giant Fosun Pharma. Existing backer include Chinese Internet company Baidu’s corporate venture arm Baidu Ventures also reinvested, the statement noted.
Jianjia Robots will use proceeds from the round to facilitate the clinical registration of its existing joint replacement surgical robots as well as to develop new line products according to the statement.
“The intelligent surgical robot system, as a new capability platform to improve the quality and efficiency of surgical operations, has proven its huge clinical potential and will follow the rapid development of AI perception [and] computing,” a Baidu Ventures executive said in the statement.
Founder Xu Jing also commenting on the deal said, “will accelerate [the development of] orthopedic surgery robots with the help of capital. The clinical trials and R&D process of the company will build a surgical robot platform enterprise and become a supplier and leader of overall solutions and personalized diagnosis and treatment for orthopedic surgery in China.”